Key Insights
The APAC Sodium Glucose Cotransporter (SGLT) Inhibitors market is poised for significant expansion, projected to reach USD 1.82 Billion by 2025, with a robust Compound Annual Growth Rate (CAGR) of 8.35% during the 2019-2033 study period. This impressive growth trajectory is driven by a confluence of factors, primarily the escalating prevalence of Type 2 Diabetes across the Asia-Pacific region, coupled with increasing healthcare expenditure and greater patient awareness. The introduction of innovative SGLT inhibitors like Invokana (Canagliflozin), Jardiance (Empagliflozin), and Farxiga/Forxiga (Dapagliflozin) has provided physicians with more effective treatment options, contributing to market penetration. Furthermore, a growing emphasis on preventative healthcare and the proactive management of comorbidities associated with diabetes, such as cardiovascular diseases and chronic kidney disease, are also fueling demand. The availability of these advanced therapeutic agents offers a compelling alternative to traditional diabetes treatments, promising improved glycemic control and added cardiovascular and renal benefits, thus solidifying their market position.
APAC Sodium Glucose Cotransporter Industry Market Size (In Billion)
The market landscape for SGLT inhibitors in APAC is characterized by dynamic competition and evolving patient needs. While drivers are strong, certain restraints could influence the pace of growth. These include the high cost of newer generation drugs, potential side effects (though generally well-managed with monitoring), and varying levels of reimbursement policies across different countries within the region. However, the persistent unmet medical needs in diabetes management and the continuous innovation pipeline from key players such as Janssen Pharmaceuticals, Eli Lilly, AstraZeneca, Bristol Myers Squibb, and Boehringer Ingelheim are expected to overcome these challenges. Geographical segmentation reveals a concentrated focus on developed markets like Japan and Australia, alongside rapidly growing economies such as China and India, which represent significant untapped potential due to their large populations and increasing diabetes burden. The Rest of Asia-Pacific, encompassing countries like South Korea, Vietnam, Malaysia, Indonesia, Philippines, and Thailand, also presents considerable opportunities for market expansion as healthcare infrastructure and access to advanced treatments improve.
APAC Sodium Glucose Cotransporter Industry Company Market Share
Uncover the dynamic growth and strategic landscape of the APAC Sodium Glucose Cotransporter (SGLT) inhibitor market. This comprehensive report delves into the intricate market dynamics, key trends, leading segments, and future opportunities within the Asia-Pacific region, from 2019 to 2033. Essential for pharmaceutical companies, healthcare providers, investors, and policy makers, this analysis provides critical insights into the evolving treatment of type 2 diabetes and related cardiovascular conditions.
APAC Sodium Glucose Cotransporter Industry Market Dynamics & Concentration
The APAC Sodium Glucose Cotransporter (SGLT) inhibitor market is characterized by a moderate to high concentration, driven by a few key pharmaceutical giants investing heavily in research and development for novel SGLT2 inhibitors. Innovation drivers include the escalating prevalence of type 2 diabetes and associated comorbidities across the region, demanding more effective and safer treatment options. Regulatory frameworks, while varying by country, are generally moving towards faster approvals for innovative therapies that demonstrate clear clinical benefits. Product substitutes exist in the form of other anti-diabetic medications (e.g., GLP-1 receptor agonists, DPP-4 inhibitors), but the unique dual benefits of SGLT inhibitors in cardiovascular and renal protection are creating a distinct market niche. End-user trends indicate a growing preference for oral medications with demonstrated long-term benefits beyond glycemic control. Mergers and acquisition (M&A) activities in this sector are less frequent but are strategically focused on acquiring novel drug candidates or expanding market reach. The estimated market share for leading SGLT inhibitor brands is a critical aspect of this analysis, with M&A deal counts currently at a low single digit, reflecting the maturity of some key product pipelines.
- Market Concentration: Moderate to High
- Innovation Drivers: Rising diabetes prevalence, demand for cardiovascular and renal benefits.
- Regulatory Frameworks: Evolving, with a trend towards faster approvals for innovative therapies.
- Product Substitutes: Other anti-diabetic drug classes, but SGLT inhibitors offer unique benefits.
- End-User Trends: Preference for oral medications with extended health benefits.
- M&A Activities: Strategically focused, low deal count.
APAC Sodium Glucose Cotransporter Industry Industry Trends & Analysis
The APAC Sodium Glucose Cotransporter (SGLT) inhibitor industry is poised for substantial growth, fueled by a confluence of factors including a rapidly expanding patient pool suffering from type 2 diabetes and an increasing awareness of the cardiovascular and renal benefits offered by SGLT2 inhibitors. The estimated Compound Annual Growth Rate (CAGR) for this market is projected to be robust, driven by rising healthcare expenditure and improved access to advanced treatments across emerging economies within the Asia-Pacific region. Technological disruptions are less about fundamental changes in SGLT inhibitor mechanisms, but rather advancements in drug delivery, combination therapies, and personalized medicine approaches. Consumer preferences are shifting towards therapies that offer multi-organ protection, moving beyond simple blood glucose reduction. This trend directly benefits SGLT inhibitors like Farxiga/Forxiga (dapagliflozin) and Jardiance (empagliflozin), which have demonstrated significant efficacy in reducing the risk of heart failure and chronic kidney disease. Competitive dynamics are intense, with key players vying for market leadership through clinical trial advancements, strategic partnerships, and aggressive market penetration strategies. The market penetration of SGLT inhibitors, while growing, still has significant room for expansion, particularly in less developed markets. The projected market size for the APAC SGLT inhibitor market is expected to reach several billion US dollars within the forecast period.
Leading Markets & Segments in APAC Sodium Glucose Cotransporter Industry
The APAC Sodium Glucose Cotransporter (SGLT) inhibitor market is dominated by specific geographical regions and product segments, each contributing uniquely to the overall market dynamics. Japan, with its aging population and high incidence of chronic diseases, represents a leading market, characterized by high treatment adherence and a well-established healthcare infrastructure. South Korea and Australia also exhibit strong market performance due to similar factors. China, with its vast population and rapidly growing middle class, presents the most significant untapped potential and is emerging as a key growth engine. India, despite its economic disparities, is witnessing increasing adoption of advanced diabetes therapies due to rising awareness and government initiatives.
Dominant Segments:
- Jardiance (Empagliflozin): This segment is a major contributor to market growth, driven by extensive clinical evidence supporting its cardiovascular and renal benefits. Its approval for broader applications, including pediatric use, further amplifies its market share.
- Farxiga/Forxiga (Dapagliflozin): Another frontrunner, Farxiga/Forxiga benefits from robust clinical data demonstrating its efficacy in heart failure and chronic kidney disease, expanding its therapeutic applications beyond diabetes.
- Invokana (Canagliflozin): While a significant player, its growth trajectory is influenced by the ongoing clinical evaluation and market positioning against its key competitors.
Key Drivers of Dominance in Leading Regions:
- Japan: High prevalence of type 2 diabetes, strong reimbursement policies, advanced clinical research capabilities, and an aging demographic.
- China: Massive patient population, increasing disposable income, growing healthcare infrastructure, and government focus on managing chronic diseases.
- Australia: Robust healthcare system, high awareness of diabetes management, and favorable market access for innovative drugs.
- South Korea: Advanced medical technology, high patient engagement in healthcare, and a strong focus on preventative medicine.
The dominance of specific products within these regions is further amplified by targeted marketing efforts, physician education programs, and strategic partnerships with local healthcare providers. The Rest of Asia-Pacific, encompassing countries like Vietnam, Malaysia, Indonesia, Philippines, and Thailand, represents a burgeoning market with significant growth potential driven by improving economies and expanding healthcare access.
APAC Sodium Glucose Cotransporter Industry Product Developments
Recent product developments in the APAC Sodium Glucose Cotransporter (SGLT) inhibitor industry are focused on expanding therapeutic indications and enhancing patient outcomes. The U.S. Food and Drug Administration's June 2023 approval of Jardiance (empagliflozin) and Synjardy for pediatric type 2 diabetes marks a significant milestone, opening a new market segment for this class of oral medications. Furthermore, AstraZeneca's November 2022 announcement of positive findings from the DELIVER Phase III trial, showcasing Farxiga (dapagliflozin)'s improvement in symptom burden and quality of life for heart failure patients, highlights the expanding role of SGLT inhibitors beyond diabetes management. These developments underscore a trend towards utilizing SGLT inhibitors for their broader cardiovascular and renal protective properties, solidifying their competitive advantage and market fit.
Key Drivers of APAC Sodium Glucose Cotransporter Industry Growth
The APAC Sodium Glucose Cotransporter (SGLT) inhibitor industry's growth is propelled by several key drivers. The alarming rise in type 2 diabetes prevalence across Asia-Pacific, coupled with an aging population, creates a substantial and expanding patient base. Crucially, increasing awareness and robust clinical evidence highlighting the significant cardiovascular and renal benefits of SGLT2 inhibitors, beyond glycemic control, are shifting treatment paradigms. Favorable regulatory environments in key markets, facilitating faster approvals for innovative therapies with proven outcomes, further accelerate adoption. Additionally, rising disposable incomes and government initiatives aimed at improving chronic disease management are enhancing market access and affordability for these advanced treatments.
Challenges in the APAC Sodium Glucose Cotransporter Industry Market
Despite its promising growth, the APAC Sodium Glucose Cotransporter (SGLT) inhibitor industry faces several challenges. Navigating diverse and sometimes complex regulatory landscapes across different Asian countries can hinder swift market entry and product localization. The high cost of these innovative therapies, compared to older anti-diabetic medications, can be a significant barrier to widespread adoption, particularly in lower-income markets. Supply chain complexities and the need for robust distribution networks to reach remote areas also pose logistical hurdles. Furthermore, intense competition from established diabetes drug classes and emerging therapies necessitates continuous innovation and strong value demonstration to maintain market share.
Emerging Opportunities in APAC Sodium Glucose Cotransporter Industry
Emerging opportunities in the APAC Sodium Glucose Cotransporter (SGLT) inhibitor industry are abundant, driven by unmet medical needs and evolving healthcare strategies. The expansion of SGLT inhibitors' indications to encompass broader cardiovascular and renal protection beyond diabetes management presents a substantial growth catalyst. Strategic partnerships with local pharmaceutical companies and healthcare providers can facilitate market penetration and tailor commercialization efforts to specific regional needs. Technological advancements in combination therapies, integrating SGLT inhibitors with other novel drug classes, offer enhanced efficacy and patient convenience. Moreover, increasing government focus on preventive healthcare and chronic disease management across the APAC region is creating a fertile ground for market expansion and increased prescription rates.
Leading Players in the APAC Sodium Glucose Cotransporter Industry Sector
- Janssen Pharmaceuticals
- Eli Lilly
- AstraZeneca
- Bristol Myers Squibb
- Boehringer Ingelheim
Key Milestones in APAC Sodium Glucose Cotransporter Industry Industry
- June 2023: The U.S. Food and Drug Administration approved Jardiance (empagliflozin) and Synjardy (empagliflozin and metformin hydrochloride) as additions to diet and exercise to improve blood sugar control in children 10 years and older with type 2 diabetes. These approvals provide a new class of medicines taken by mouth to treat pediatric type 2 diabetes.
- November 2022: AstraZeneca announced new findings from a pre-specified DELIVER Phase III trial data analysis. It shows that Farxiga (dapagliflozin) improved symptom burden and health-related quality of life in patients with heart failure and mildly reduced or preserved ejection fraction compared with a placebo.
Strategic Outlook for APAC Sodium Glucose Cotransporter Industry Market
The strategic outlook for the APAC Sodium Glucose Cotransporter (SGLT) inhibitor market is one of sustained and significant expansion. The continued increase in type 2 diabetes and the growing recognition of SGLT inhibitors' dual benefits in managing cardiovascular and renal diseases will be primary growth accelerators. Manufacturers are expected to focus on expanding approved indications, particularly in the cardiovascular and nephrology space, further solidifying their market position. Strategic collaborations and partnerships within the region will be crucial for navigating diverse regulatory environments and enhancing market access. Investing in robust post-market surveillance and real-world evidence generation will further strengthen the value proposition of these therapies, paving the way for increased adoption and improved patient outcomes across the Asia-Pacific.
APAC Sodium Glucose Cotransporter Industry Segmentation
- 1. Invokana (Canagliflozin)
- 2. Jardiance (Empagliflozin)
- 3. Farxiga/Forxiga (Dapagliflozin)
- 4. Suglat (Ipragliflozin)
-
5. Geography
- 5.1. Japan
- 5.2. South Korea
- 5.3. China
- 5.4. India
- 5.5. Australia
- 5.6. Vietnam
- 5.7. Malaysia
- 5.8. Indonesia
- 5.9. Philippines
- 5.10. Thailand
- 5.11. Rest of Asia-Pacific
APAC Sodium Glucose Cotransporter Industry Segmentation By Geography
- 1. Japan
- 2. South Korea
- 3. China
- 4. India
- 5. Australia
- 6. Vietnam
- 7. Malaysia
- 8. Indonesia
- 9. Philippines
- 10. Thailand
- 11. Rest of Asia Pacific
APAC Sodium Glucose Cotransporter Industry Regional Market Share
Geographic Coverage of APAC Sodium Glucose Cotransporter Industry
APAC Sodium Glucose Cotransporter Industry REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of 8.35% from 2020-2034 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Increasing Prevalence of Genitourinary Disorders; Increasing Number of Pipeline Products
- 3.3. Market Restrains
- 3.3.1. Lack of Therapy Compliance; Increasing Advent of Counterfeit Drugs
- 3.4. Market Trends
- 3.4.1. Jardiance Segment holds the highest market share in the Asia-Pacific Sodium-dependent Glucose Cotransporter 2 (SGLT-2) Market in the current year
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Global APAC Sodium Glucose Cotransporter Industry Analysis, Insights and Forecast, 2020-2032
- 5.1. Market Analysis, Insights and Forecast - by Invokana (Canagliflozin)
- 5.2. Market Analysis, Insights and Forecast - by Jardiance (Empagliflozin)
- 5.3. Market Analysis, Insights and Forecast - by Farxiga/Forxiga (Dapagliflozin)
- 5.4. Market Analysis, Insights and Forecast - by Suglat (Ipragliflozin)
- 5.5. Market Analysis, Insights and Forecast - by Geography
- 5.5.1. Japan
- 5.5.2. South Korea
- 5.5.3. China
- 5.5.4. India
- 5.5.5. Australia
- 5.5.6. Vietnam
- 5.5.7. Malaysia
- 5.5.8. Indonesia
- 5.5.9. Philippines
- 5.5.10. Thailand
- 5.5.11. Rest of Asia-Pacific
- 5.6. Market Analysis, Insights and Forecast - by Region
- 5.6.1. Japan
- 5.6.2. South Korea
- 5.6.3. China
- 5.6.4. India
- 5.6.5. Australia
- 5.6.6. Vietnam
- 5.6.7. Malaysia
- 5.6.8. Indonesia
- 5.6.9. Philippines
- 5.6.10. Thailand
- 5.6.11. Rest of Asia Pacific
- 5.1. Market Analysis, Insights and Forecast - by Invokana (Canagliflozin)
- 6. Japan APAC Sodium Glucose Cotransporter Industry Analysis, Insights and Forecast, 2020-2032
- 6.1. Market Analysis, Insights and Forecast - by Invokana (Canagliflozin)
- 6.2. Market Analysis, Insights and Forecast - by Jardiance (Empagliflozin)
- 6.3. Market Analysis, Insights and Forecast - by Farxiga/Forxiga (Dapagliflozin)
- 6.4. Market Analysis, Insights and Forecast - by Suglat (Ipragliflozin)
- 6.5. Market Analysis, Insights and Forecast - by Geography
- 6.5.1. Japan
- 6.5.2. South Korea
- 6.5.3. China
- 6.5.4. India
- 6.5.5. Australia
- 6.5.6. Vietnam
- 6.5.7. Malaysia
- 6.5.8. Indonesia
- 6.5.9. Philippines
- 6.5.10. Thailand
- 6.5.11. Rest of Asia-Pacific
- 6.1. Market Analysis, Insights and Forecast - by Invokana (Canagliflozin)
- 7. South Korea APAC Sodium Glucose Cotransporter Industry Analysis, Insights and Forecast, 2020-2032
- 7.1. Market Analysis, Insights and Forecast - by Invokana (Canagliflozin)
- 7.2. Market Analysis, Insights and Forecast - by Jardiance (Empagliflozin)
- 7.3. Market Analysis, Insights and Forecast - by Farxiga/Forxiga (Dapagliflozin)
- 7.4. Market Analysis, Insights and Forecast - by Suglat (Ipragliflozin)
- 7.5. Market Analysis, Insights and Forecast - by Geography
- 7.5.1. Japan
- 7.5.2. South Korea
- 7.5.3. China
- 7.5.4. India
- 7.5.5. Australia
- 7.5.6. Vietnam
- 7.5.7. Malaysia
- 7.5.8. Indonesia
- 7.5.9. Philippines
- 7.5.10. Thailand
- 7.5.11. Rest of Asia-Pacific
- 7.1. Market Analysis, Insights and Forecast - by Invokana (Canagliflozin)
- 8. China APAC Sodium Glucose Cotransporter Industry Analysis, Insights and Forecast, 2020-2032
- 8.1. Market Analysis, Insights and Forecast - by Invokana (Canagliflozin)
- 8.2. Market Analysis, Insights and Forecast - by Jardiance (Empagliflozin)
- 8.3. Market Analysis, Insights and Forecast - by Farxiga/Forxiga (Dapagliflozin)
- 8.4. Market Analysis, Insights and Forecast - by Suglat (Ipragliflozin)
- 8.5. Market Analysis, Insights and Forecast - by Geography
- 8.5.1. Japan
- 8.5.2. South Korea
- 8.5.3. China
- 8.5.4. India
- 8.5.5. Australia
- 8.5.6. Vietnam
- 8.5.7. Malaysia
- 8.5.8. Indonesia
- 8.5.9. Philippines
- 8.5.10. Thailand
- 8.5.11. Rest of Asia-Pacific
- 8.1. Market Analysis, Insights and Forecast - by Invokana (Canagliflozin)
- 9. India APAC Sodium Glucose Cotransporter Industry Analysis, Insights and Forecast, 2020-2032
- 9.1. Market Analysis, Insights and Forecast - by Invokana (Canagliflozin)
- 9.2. Market Analysis, Insights and Forecast - by Jardiance (Empagliflozin)
- 9.3. Market Analysis, Insights and Forecast - by Farxiga/Forxiga (Dapagliflozin)
- 9.4. Market Analysis, Insights and Forecast - by Suglat (Ipragliflozin)
- 9.5. Market Analysis, Insights and Forecast - by Geography
- 9.5.1. Japan
- 9.5.2. South Korea
- 9.5.3. China
- 9.5.4. India
- 9.5.5. Australia
- 9.5.6. Vietnam
- 9.5.7. Malaysia
- 9.5.8. Indonesia
- 9.5.9. Philippines
- 9.5.10. Thailand
- 9.5.11. Rest of Asia-Pacific
- 9.1. Market Analysis, Insights and Forecast - by Invokana (Canagliflozin)
- 10. Australia APAC Sodium Glucose Cotransporter Industry Analysis, Insights and Forecast, 2020-2032
- 10.1. Market Analysis, Insights and Forecast - by Invokana (Canagliflozin)
- 10.2. Market Analysis, Insights and Forecast - by Jardiance (Empagliflozin)
- 10.3. Market Analysis, Insights and Forecast - by Farxiga/Forxiga (Dapagliflozin)
- 10.4. Market Analysis, Insights and Forecast - by Suglat (Ipragliflozin)
- 10.5. Market Analysis, Insights and Forecast - by Geography
- 10.5.1. Japan
- 10.5.2. South Korea
- 10.5.3. China
- 10.5.4. India
- 10.5.5. Australia
- 10.5.6. Vietnam
- 10.5.7. Malaysia
- 10.5.8. Indonesia
- 10.5.9. Philippines
- 10.5.10. Thailand
- 10.5.11. Rest of Asia-Pacific
- 10.1. Market Analysis, Insights and Forecast - by Invokana (Canagliflozin)
- 11. Vietnam APAC Sodium Glucose Cotransporter Industry Analysis, Insights and Forecast, 2020-2032
- 11.1. Market Analysis, Insights and Forecast - by Invokana (Canagliflozin)
- 11.2. Market Analysis, Insights and Forecast - by Jardiance (Empagliflozin)
- 11.3. Market Analysis, Insights and Forecast - by Farxiga/Forxiga (Dapagliflozin)
- 11.4. Market Analysis, Insights and Forecast - by Suglat (Ipragliflozin)
- 11.5. Market Analysis, Insights and Forecast - by Geography
- 11.5.1. Japan
- 11.5.2. South Korea
- 11.5.3. China
- 11.5.4. India
- 11.5.5. Australia
- 11.5.6. Vietnam
- 11.5.7. Malaysia
- 11.5.8. Indonesia
- 11.5.9. Philippines
- 11.5.10. Thailand
- 11.5.11. Rest of Asia-Pacific
- 11.1. Market Analysis, Insights and Forecast - by Invokana (Canagliflozin)
- 12. Malaysia APAC Sodium Glucose Cotransporter Industry Analysis, Insights and Forecast, 2020-2032
- 12.1. Market Analysis, Insights and Forecast - by Invokana (Canagliflozin)
- 12.2. Market Analysis, Insights and Forecast - by Jardiance (Empagliflozin)
- 12.3. Market Analysis, Insights and Forecast - by Farxiga/Forxiga (Dapagliflozin)
- 12.4. Market Analysis, Insights and Forecast - by Suglat (Ipragliflozin)
- 12.5. Market Analysis, Insights and Forecast - by Geography
- 12.5.1. Japan
- 12.5.2. South Korea
- 12.5.3. China
- 12.5.4. India
- 12.5.5. Australia
- 12.5.6. Vietnam
- 12.5.7. Malaysia
- 12.5.8. Indonesia
- 12.5.9. Philippines
- 12.5.10. Thailand
- 12.5.11. Rest of Asia-Pacific
- 12.1. Market Analysis, Insights and Forecast - by Invokana (Canagliflozin)
- 13. Indonesia APAC Sodium Glucose Cotransporter Industry Analysis, Insights and Forecast, 2020-2032
- 13.1. Market Analysis, Insights and Forecast - by Invokana (Canagliflozin)
- 13.2. Market Analysis, Insights and Forecast - by Jardiance (Empagliflozin)
- 13.3. Market Analysis, Insights and Forecast - by Farxiga/Forxiga (Dapagliflozin)
- 13.4. Market Analysis, Insights and Forecast - by Suglat (Ipragliflozin)
- 13.5. Market Analysis, Insights and Forecast - by Geography
- 13.5.1. Japan
- 13.5.2. South Korea
- 13.5.3. China
- 13.5.4. India
- 13.5.5. Australia
- 13.5.6. Vietnam
- 13.5.7. Malaysia
- 13.5.8. Indonesia
- 13.5.9. Philippines
- 13.5.10. Thailand
- 13.5.11. Rest of Asia-Pacific
- 13.1. Market Analysis, Insights and Forecast - by Invokana (Canagliflozin)
- 14. Philippines APAC Sodium Glucose Cotransporter Industry Analysis, Insights and Forecast, 2020-2032
- 14.1. Market Analysis, Insights and Forecast - by Invokana (Canagliflozin)
- 14.2. Market Analysis, Insights and Forecast - by Jardiance (Empagliflozin)
- 14.3. Market Analysis, Insights and Forecast - by Farxiga/Forxiga (Dapagliflozin)
- 14.4. Market Analysis, Insights and Forecast - by Suglat (Ipragliflozin)
- 14.5. Market Analysis, Insights and Forecast - by Geography
- 14.5.1. Japan
- 14.5.2. South Korea
- 14.5.3. China
- 14.5.4. India
- 14.5.5. Australia
- 14.5.6. Vietnam
- 14.5.7. Malaysia
- 14.5.8. Indonesia
- 14.5.9. Philippines
- 14.5.10. Thailand
- 14.5.11. Rest of Asia-Pacific
- 14.1. Market Analysis, Insights and Forecast - by Invokana (Canagliflozin)
- 15. Thailand APAC Sodium Glucose Cotransporter Industry Analysis, Insights and Forecast, 2020-2032
- 15.1. Market Analysis, Insights and Forecast - by Invokana (Canagliflozin)
- 15.2. Market Analysis, Insights and Forecast - by Jardiance (Empagliflozin)
- 15.3. Market Analysis, Insights and Forecast - by Farxiga/Forxiga (Dapagliflozin)
- 15.4. Market Analysis, Insights and Forecast - by Suglat (Ipragliflozin)
- 15.5. Market Analysis, Insights and Forecast - by Geography
- 15.5.1. Japan
- 15.5.2. South Korea
- 15.5.3. China
- 15.5.4. India
- 15.5.5. Australia
- 15.5.6. Vietnam
- 15.5.7. Malaysia
- 15.5.8. Indonesia
- 15.5.9. Philippines
- 15.5.10. Thailand
- 15.5.11. Rest of Asia-Pacific
- 15.1. Market Analysis, Insights and Forecast - by Invokana (Canagliflozin)
- 16. Rest of Asia Pacific APAC Sodium Glucose Cotransporter Industry Analysis, Insights and Forecast, 2020-2032
- 16.1. Market Analysis, Insights and Forecast - by Invokana (Canagliflozin)
- 16.2. Market Analysis, Insights and Forecast - by Jardiance (Empagliflozin)
- 16.3. Market Analysis, Insights and Forecast - by Farxiga/Forxiga (Dapagliflozin)
- 16.4. Market Analysis, Insights and Forecast - by Suglat (Ipragliflozin)
- 16.5. Market Analysis, Insights and Forecast - by Geography
- 16.5.1. Japan
- 16.5.2. South Korea
- 16.5.3. China
- 16.5.4. India
- 16.5.5. Australia
- 16.5.6. Vietnam
- 16.5.7. Malaysia
- 16.5.8. Indonesia
- 16.5.9. Philippines
- 16.5.10. Thailand
- 16.5.11. Rest of Asia-Pacific
- 16.1. Market Analysis, Insights and Forecast - by Invokana (Canagliflozin)
- 17. Competitive Analysis
- 17.1. Global Market Share Analysis 2025
- 17.2. Company Profiles
- 17.2.1 Janssen Pharmaceuticals
- 17.2.1.1. Overview
- 17.2.1.2. Products
- 17.2.1.3. SWOT Analysis
- 17.2.1.4. Recent Developments
- 17.2.1.5. Financials (Based on Availability)
- 17.2.2 Eli Lilly
- 17.2.2.1. Overview
- 17.2.2.2. Products
- 17.2.2.3. SWOT Analysis
- 17.2.2.4. Recent Developments
- 17.2.2.5. Financials (Based on Availability)
- 17.2.3 AstraZeneca
- 17.2.3.1. Overview
- 17.2.3.2. Products
- 17.2.3.3. SWOT Analysis
- 17.2.3.4. Recent Developments
- 17.2.3.5. Financials (Based on Availability)
- 17.2.4 Bristol Myers Squibb*List Not Exhaustive 7 2 MARKET SHARE ANALYSI
- 17.2.4.1. Overview
- 17.2.4.2. Products
- 17.2.4.3. SWOT Analysis
- 17.2.4.4. Recent Developments
- 17.2.4.5. Financials (Based on Availability)
- 17.2.5 Boehringer Ingelheim
- 17.2.5.1. Overview
- 17.2.5.2. Products
- 17.2.5.3. SWOT Analysis
- 17.2.5.4. Recent Developments
- 17.2.5.5. Financials (Based on Availability)
- 17.2.1 Janssen Pharmaceuticals
List of Figures
- Figure 1: Global APAC Sodium Glucose Cotransporter Industry Revenue Breakdown (Million, %) by Region 2025 & 2033
- Figure 2: Japan APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Invokana (Canagliflozin) 2025 & 2033
- Figure 3: Japan APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Invokana (Canagliflozin) 2025 & 2033
- Figure 4: Japan APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Jardiance (Empagliflozin) 2025 & 2033
- Figure 5: Japan APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Jardiance (Empagliflozin) 2025 & 2033
- Figure 6: Japan APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Farxiga/Forxiga (Dapagliflozin) 2025 & 2033
- Figure 7: Japan APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Farxiga/Forxiga (Dapagliflozin) 2025 & 2033
- Figure 8: Japan APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Suglat (Ipragliflozin) 2025 & 2033
- Figure 9: Japan APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Suglat (Ipragliflozin) 2025 & 2033
- Figure 10: Japan APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Geography 2025 & 2033
- Figure 11: Japan APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Geography 2025 & 2033
- Figure 12: Japan APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Country 2025 & 2033
- Figure 13: Japan APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Country 2025 & 2033
- Figure 14: South Korea APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Invokana (Canagliflozin) 2025 & 2033
- Figure 15: South Korea APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Invokana (Canagliflozin) 2025 & 2033
- Figure 16: South Korea APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Jardiance (Empagliflozin) 2025 & 2033
- Figure 17: South Korea APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Jardiance (Empagliflozin) 2025 & 2033
- Figure 18: South Korea APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Farxiga/Forxiga (Dapagliflozin) 2025 & 2033
- Figure 19: South Korea APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Farxiga/Forxiga (Dapagliflozin) 2025 & 2033
- Figure 20: South Korea APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Suglat (Ipragliflozin) 2025 & 2033
- Figure 21: South Korea APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Suglat (Ipragliflozin) 2025 & 2033
- Figure 22: South Korea APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Geography 2025 & 2033
- Figure 23: South Korea APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Geography 2025 & 2033
- Figure 24: South Korea APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Country 2025 & 2033
- Figure 25: South Korea APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Country 2025 & 2033
- Figure 26: China APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Invokana (Canagliflozin) 2025 & 2033
- Figure 27: China APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Invokana (Canagliflozin) 2025 & 2033
- Figure 28: China APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Jardiance (Empagliflozin) 2025 & 2033
- Figure 29: China APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Jardiance (Empagliflozin) 2025 & 2033
- Figure 30: China APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Farxiga/Forxiga (Dapagliflozin) 2025 & 2033
- Figure 31: China APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Farxiga/Forxiga (Dapagliflozin) 2025 & 2033
- Figure 32: China APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Suglat (Ipragliflozin) 2025 & 2033
- Figure 33: China APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Suglat (Ipragliflozin) 2025 & 2033
- Figure 34: China APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Geography 2025 & 2033
- Figure 35: China APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Geography 2025 & 2033
- Figure 36: China APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Country 2025 & 2033
- Figure 37: China APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Country 2025 & 2033
- Figure 38: India APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Invokana (Canagliflozin) 2025 & 2033
- Figure 39: India APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Invokana (Canagliflozin) 2025 & 2033
- Figure 40: India APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Jardiance (Empagliflozin) 2025 & 2033
- Figure 41: India APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Jardiance (Empagliflozin) 2025 & 2033
- Figure 42: India APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Farxiga/Forxiga (Dapagliflozin) 2025 & 2033
- Figure 43: India APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Farxiga/Forxiga (Dapagliflozin) 2025 & 2033
- Figure 44: India APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Suglat (Ipragliflozin) 2025 & 2033
- Figure 45: India APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Suglat (Ipragliflozin) 2025 & 2033
- Figure 46: India APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Geography 2025 & 2033
- Figure 47: India APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Geography 2025 & 2033
- Figure 48: India APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Country 2025 & 2033
- Figure 49: India APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Country 2025 & 2033
- Figure 50: Australia APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Invokana (Canagliflozin) 2025 & 2033
- Figure 51: Australia APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Invokana (Canagliflozin) 2025 & 2033
- Figure 52: Australia APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Jardiance (Empagliflozin) 2025 & 2033
- Figure 53: Australia APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Jardiance (Empagliflozin) 2025 & 2033
- Figure 54: Australia APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Farxiga/Forxiga (Dapagliflozin) 2025 & 2033
- Figure 55: Australia APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Farxiga/Forxiga (Dapagliflozin) 2025 & 2033
- Figure 56: Australia APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Suglat (Ipragliflozin) 2025 & 2033
- Figure 57: Australia APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Suglat (Ipragliflozin) 2025 & 2033
- Figure 58: Australia APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Geography 2025 & 2033
- Figure 59: Australia APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Geography 2025 & 2033
- Figure 60: Australia APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Country 2025 & 2033
- Figure 61: Australia APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Country 2025 & 2033
- Figure 62: Vietnam APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Invokana (Canagliflozin) 2025 & 2033
- Figure 63: Vietnam APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Invokana (Canagliflozin) 2025 & 2033
- Figure 64: Vietnam APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Jardiance (Empagliflozin) 2025 & 2033
- Figure 65: Vietnam APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Jardiance (Empagliflozin) 2025 & 2033
- Figure 66: Vietnam APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Farxiga/Forxiga (Dapagliflozin) 2025 & 2033
- Figure 67: Vietnam APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Farxiga/Forxiga (Dapagliflozin) 2025 & 2033
- Figure 68: Vietnam APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Suglat (Ipragliflozin) 2025 & 2033
- Figure 69: Vietnam APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Suglat (Ipragliflozin) 2025 & 2033
- Figure 70: Vietnam APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Geography 2025 & 2033
- Figure 71: Vietnam APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Geography 2025 & 2033
- Figure 72: Vietnam APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Country 2025 & 2033
- Figure 73: Vietnam APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Country 2025 & 2033
- Figure 74: Malaysia APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Invokana (Canagliflozin) 2025 & 2033
- Figure 75: Malaysia APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Invokana (Canagliflozin) 2025 & 2033
- Figure 76: Malaysia APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Jardiance (Empagliflozin) 2025 & 2033
- Figure 77: Malaysia APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Jardiance (Empagliflozin) 2025 & 2033
- Figure 78: Malaysia APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Farxiga/Forxiga (Dapagliflozin) 2025 & 2033
- Figure 79: Malaysia APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Farxiga/Forxiga (Dapagliflozin) 2025 & 2033
- Figure 80: Malaysia APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Suglat (Ipragliflozin) 2025 & 2033
- Figure 81: Malaysia APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Suglat (Ipragliflozin) 2025 & 2033
- Figure 82: Malaysia APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Geography 2025 & 2033
- Figure 83: Malaysia APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Geography 2025 & 2033
- Figure 84: Malaysia APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Country 2025 & 2033
- Figure 85: Malaysia APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Country 2025 & 2033
- Figure 86: Indonesia APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Invokana (Canagliflozin) 2025 & 2033
- Figure 87: Indonesia APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Invokana (Canagliflozin) 2025 & 2033
- Figure 88: Indonesia APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Jardiance (Empagliflozin) 2025 & 2033
- Figure 89: Indonesia APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Jardiance (Empagliflozin) 2025 & 2033
- Figure 90: Indonesia APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Farxiga/Forxiga (Dapagliflozin) 2025 & 2033
- Figure 91: Indonesia APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Farxiga/Forxiga (Dapagliflozin) 2025 & 2033
- Figure 92: Indonesia APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Suglat (Ipragliflozin) 2025 & 2033
- Figure 93: Indonesia APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Suglat (Ipragliflozin) 2025 & 2033
- Figure 94: Indonesia APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Geography 2025 & 2033
- Figure 95: Indonesia APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Geography 2025 & 2033
- Figure 96: Indonesia APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Country 2025 & 2033
- Figure 97: Indonesia APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Country 2025 & 2033
- Figure 98: Philippines APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Invokana (Canagliflozin) 2025 & 2033
- Figure 99: Philippines APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Invokana (Canagliflozin) 2025 & 2033
- Figure 100: Philippines APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Jardiance (Empagliflozin) 2025 & 2033
- Figure 101: Philippines APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Jardiance (Empagliflozin) 2025 & 2033
- Figure 102: Philippines APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Farxiga/Forxiga (Dapagliflozin) 2025 & 2033
- Figure 103: Philippines APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Farxiga/Forxiga (Dapagliflozin) 2025 & 2033
- Figure 104: Philippines APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Suglat (Ipragliflozin) 2025 & 2033
- Figure 105: Philippines APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Suglat (Ipragliflozin) 2025 & 2033
- Figure 106: Philippines APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Geography 2025 & 2033
- Figure 107: Philippines APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Geography 2025 & 2033
- Figure 108: Philippines APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Country 2025 & 2033
- Figure 109: Philippines APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Country 2025 & 2033
- Figure 110: Thailand APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Invokana (Canagliflozin) 2025 & 2033
- Figure 111: Thailand APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Invokana (Canagliflozin) 2025 & 2033
- Figure 112: Thailand APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Jardiance (Empagliflozin) 2025 & 2033
- Figure 113: Thailand APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Jardiance (Empagliflozin) 2025 & 2033
- Figure 114: Thailand APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Farxiga/Forxiga (Dapagliflozin) 2025 & 2033
- Figure 115: Thailand APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Farxiga/Forxiga (Dapagliflozin) 2025 & 2033
- Figure 116: Thailand APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Suglat (Ipragliflozin) 2025 & 2033
- Figure 117: Thailand APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Suglat (Ipragliflozin) 2025 & 2033
- Figure 118: Thailand APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Geography 2025 & 2033
- Figure 119: Thailand APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Geography 2025 & 2033
- Figure 120: Thailand APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Country 2025 & 2033
- Figure 121: Thailand APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Country 2025 & 2033
- Figure 122: Rest of Asia Pacific APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Invokana (Canagliflozin) 2025 & 2033
- Figure 123: Rest of Asia Pacific APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Invokana (Canagliflozin) 2025 & 2033
- Figure 124: Rest of Asia Pacific APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Jardiance (Empagliflozin) 2025 & 2033
- Figure 125: Rest of Asia Pacific APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Jardiance (Empagliflozin) 2025 & 2033
- Figure 126: Rest of Asia Pacific APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Farxiga/Forxiga (Dapagliflozin) 2025 & 2033
- Figure 127: Rest of Asia Pacific APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Farxiga/Forxiga (Dapagliflozin) 2025 & 2033
- Figure 128: Rest of Asia Pacific APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Suglat (Ipragliflozin) 2025 & 2033
- Figure 129: Rest of Asia Pacific APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Suglat (Ipragliflozin) 2025 & 2033
- Figure 130: Rest of Asia Pacific APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Geography 2025 & 2033
- Figure 131: Rest of Asia Pacific APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Geography 2025 & 2033
- Figure 132: Rest of Asia Pacific APAC Sodium Glucose Cotransporter Industry Revenue (Million), by Country 2025 & 2033
- Figure 133: Rest of Asia Pacific APAC Sodium Glucose Cotransporter Industry Revenue Share (%), by Country 2025 & 2033
List of Tables
- Table 1: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Invokana (Canagliflozin) 2020 & 2033
- Table 2: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Jardiance (Empagliflozin) 2020 & 2033
- Table 3: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Farxiga/Forxiga (Dapagliflozin) 2020 & 2033
- Table 4: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Suglat (Ipragliflozin) 2020 & 2033
- Table 5: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Geography 2020 & 2033
- Table 6: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Region 2020 & 2033
- Table 7: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Invokana (Canagliflozin) 2020 & 2033
- Table 8: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Jardiance (Empagliflozin) 2020 & 2033
- Table 9: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Farxiga/Forxiga (Dapagliflozin) 2020 & 2033
- Table 10: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Suglat (Ipragliflozin) 2020 & 2033
- Table 11: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Geography 2020 & 2033
- Table 12: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Country 2020 & 2033
- Table 13: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Invokana (Canagliflozin) 2020 & 2033
- Table 14: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Jardiance (Empagliflozin) 2020 & 2033
- Table 15: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Farxiga/Forxiga (Dapagliflozin) 2020 & 2033
- Table 16: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Suglat (Ipragliflozin) 2020 & 2033
- Table 17: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Geography 2020 & 2033
- Table 18: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Country 2020 & 2033
- Table 19: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Invokana (Canagliflozin) 2020 & 2033
- Table 20: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Jardiance (Empagliflozin) 2020 & 2033
- Table 21: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Farxiga/Forxiga (Dapagliflozin) 2020 & 2033
- Table 22: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Suglat (Ipragliflozin) 2020 & 2033
- Table 23: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Geography 2020 & 2033
- Table 24: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Country 2020 & 2033
- Table 25: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Invokana (Canagliflozin) 2020 & 2033
- Table 26: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Jardiance (Empagliflozin) 2020 & 2033
- Table 27: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Farxiga/Forxiga (Dapagliflozin) 2020 & 2033
- Table 28: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Suglat (Ipragliflozin) 2020 & 2033
- Table 29: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Geography 2020 & 2033
- Table 30: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Country 2020 & 2033
- Table 31: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Invokana (Canagliflozin) 2020 & 2033
- Table 32: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Jardiance (Empagliflozin) 2020 & 2033
- Table 33: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Farxiga/Forxiga (Dapagliflozin) 2020 & 2033
- Table 34: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Suglat (Ipragliflozin) 2020 & 2033
- Table 35: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Geography 2020 & 2033
- Table 36: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Country 2020 & 2033
- Table 37: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Invokana (Canagliflozin) 2020 & 2033
- Table 38: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Jardiance (Empagliflozin) 2020 & 2033
- Table 39: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Farxiga/Forxiga (Dapagliflozin) 2020 & 2033
- Table 40: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Suglat (Ipragliflozin) 2020 & 2033
- Table 41: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Geography 2020 & 2033
- Table 42: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Country 2020 & 2033
- Table 43: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Invokana (Canagliflozin) 2020 & 2033
- Table 44: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Jardiance (Empagliflozin) 2020 & 2033
- Table 45: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Farxiga/Forxiga (Dapagliflozin) 2020 & 2033
- Table 46: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Suglat (Ipragliflozin) 2020 & 2033
- Table 47: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Geography 2020 & 2033
- Table 48: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Country 2020 & 2033
- Table 49: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Invokana (Canagliflozin) 2020 & 2033
- Table 50: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Jardiance (Empagliflozin) 2020 & 2033
- Table 51: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Farxiga/Forxiga (Dapagliflozin) 2020 & 2033
- Table 52: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Suglat (Ipragliflozin) 2020 & 2033
- Table 53: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Geography 2020 & 2033
- Table 54: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Country 2020 & 2033
- Table 55: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Invokana (Canagliflozin) 2020 & 2033
- Table 56: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Jardiance (Empagliflozin) 2020 & 2033
- Table 57: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Farxiga/Forxiga (Dapagliflozin) 2020 & 2033
- Table 58: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Suglat (Ipragliflozin) 2020 & 2033
- Table 59: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Geography 2020 & 2033
- Table 60: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Country 2020 & 2033
- Table 61: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Invokana (Canagliflozin) 2020 & 2033
- Table 62: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Jardiance (Empagliflozin) 2020 & 2033
- Table 63: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Farxiga/Forxiga (Dapagliflozin) 2020 & 2033
- Table 64: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Suglat (Ipragliflozin) 2020 & 2033
- Table 65: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Geography 2020 & 2033
- Table 66: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Country 2020 & 2033
- Table 67: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Invokana (Canagliflozin) 2020 & 2033
- Table 68: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Jardiance (Empagliflozin) 2020 & 2033
- Table 69: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Farxiga/Forxiga (Dapagliflozin) 2020 & 2033
- Table 70: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Suglat (Ipragliflozin) 2020 & 2033
- Table 71: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Geography 2020 & 2033
- Table 72: Global APAC Sodium Glucose Cotransporter Industry Revenue Million Forecast, by Country 2020 & 2033
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the APAC Sodium Glucose Cotransporter Industry?
The projected CAGR is approximately 8.35%.
2. Which companies are prominent players in the APAC Sodium Glucose Cotransporter Industry?
Key companies in the market include Janssen Pharmaceuticals, Eli Lilly, AstraZeneca, Bristol Myers Squibb*List Not Exhaustive 7 2 MARKET SHARE ANALYSI, Boehringer Ingelheim.
3. What are the main segments of the APAC Sodium Glucose Cotransporter Industry?
The market segments include Invokana (Canagliflozin), Jardiance (Empagliflozin), Farxiga/Forxiga (Dapagliflozin), Suglat (Ipragliflozin), Geography.
4. Can you provide details about the market size?
The market size is estimated to be USD 1.82 Million as of 2022.
5. What are some drivers contributing to market growth?
Increasing Prevalence of Genitourinary Disorders; Increasing Number of Pipeline Products.
6. What are the notable trends driving market growth?
Jardiance Segment holds the highest market share in the Asia-Pacific Sodium-dependent Glucose Cotransporter 2 (SGLT-2) Market in the current year.
7. Are there any restraints impacting market growth?
Lack of Therapy Compliance; Increasing Advent of Counterfeit Drugs.
8. Can you provide examples of recent developments in the market?
June 2023: the U.S. Food and Drug Administration approved Jardiance (empagliflozin) and Synjardy (empagliflozin and metformin hydrochloride) as additions to diet and exercise to improve blood sugar control in children 10 years and older with type 2 diabetes. These approvals provide a new class of medicines taken by mouth to treat pediatric type 2 diabetes.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in Million.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "APAC Sodium Glucose Cotransporter Industry," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the APAC Sodium Glucose Cotransporter Industry report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the APAC Sodium Glucose Cotransporter Industry?
To stay informed about further developments, trends, and reports in the APAC Sodium Glucose Cotransporter Industry, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence